Callyope, a Paris, France-based AI-based mental health monitoring company, has secured €2.2 million in equity funding.
SaaS Investors
The round was co-led by 360 Capital and BPI Digital Venture, with participation from No Label Ventures and business angels including Thomas Clozel (Co-founder and CEO of Owkin) and Adrien Montfort (Co-founder & CTO of Sorare).
360 Capital is a venture capital firm that prefers to invest in the pre-seed round to series B round of startups operating in deep tech, business process automation, and consumer disruption sectors. Founded in 1997 and is based in Paris, France.
BPI Digital Venture is the venture capital team of Bpifrance Investment, the French Sovereign Wealth Fund, which focuses on top-tier innovative early-stage start-ups. BPI Digital Venture targets high-potential tech companies and makes around 15 investments a year, from seed to Series B.
Callyope Use of Funds
The funds will be used to expand the company's network of research partners globally, enhance machine learning technologies, and advance its regulatory roadmap.
About Callyope
Callyope is developing a speech-based remote patient monitoring platform for individuals with schizophrenia, major depression, and bipolar disorders. The platform is powered by machine learning technologies that securely analyze acoustic and linguistic patterns to monitor patient symptoms. Callyope enables psychiatrists to deliver personalized and outcome-based care with remote patient monitoring capabilities. Callyope's technology analyzes the patient's speech to predict psychiatric clinical scores, assess fatigue, and estimate cognition deficits.
Funding Details
Company: Callyope
Raised: €2.2M
Round: Equity
Funding Month: November 2023
Lead Investors: 360 Capital and BPI Digital Venture
Additional Investors: No Label Ventures, Thomas Clozel, and Adrien Montfort
Company Website: https://callyope.com/
Software Category: AI-based Mental Health Monitoring
Source: https://tech.eu/2023/11/22/investors-back-callyope-s-ai-tool-for-treating-mental-health-conditions-with-2-2m-equity-funding/